/PRCT
PRCT Stock - PROCEPT BioRobotics Corporation
Healthcare|Medical - DevicesNASDAQ
$32.06-2.05%
$0.67 (-2.05%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.14
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+63.1%upside
Target: $52.29
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$31.74 – $32.38
TARGET (TP)$52.29
STOP LOSS$29.50
RISK/REWARD1:7.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.99
52W High$89.49
52W Low$27.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $224.50M | $136.19M | $75.01M | $34.47M | $7.72M |
| Gross Profit | $137.10M | $71.05M | $37.09M | $15.87M | $-1,255,000 |
| Gross Margin | 61.1% | 52.2% | 49.4% | 46.0% | -16.3% |
| Operating Income | $-96,614,000 | $-109,170,000 | $-80,724,000 | $-54,164,000 | $-47,802,000 |
| Net Income | $-91,413,000 | $-105,897,000 | $-87,154,000 | $-59,853,000 | $-53,019,000 |
| Net Margin | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% |
| EPS | $-1.75 | $-2.24 | $-1.96 | $-3.63 | $-1.51 |
Company Overview
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
63%
Hold / Neutral
3
38%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish3 Neutral/Bearish
Price Targets
$62
Average Target
↑ 92.5% Upside
Now
$38
Low
$62
Average
$105
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | UBS | Initiation | Buy | $62 |
| December 8th 2025 | BofA Securities | Downgrade | Neutral | $38 |
| September 2nd 2025 | Oppenheimer | Upgrade | Outperform | $60 |
| July 9th 2025 | Stephens | Initiation | Overweight | $70 |
| July 7th 2025 | Oppenheimer | Initiation | Perform | - |
| December 2nd 2024 | Morgan Stanley | Initiation | Overweight | $105 |
| November 14th 2024 | Jefferies | Initiation | Hold | $95 |
| August 11th 2023 | Piper Sandler | Initiation | Overweight | $42 |
| May 31st 2023 | William Blair | Initiation | Outperform | - |
| October 31st 2022 | BTIG Research | Initiation | Neutral | - |
| October 25th 2022 | Truist | Initiation | Buy | $58 |
| September 2nd 2022 | Wells Fargo | Initiation | Overweight | $49 |
| July 15th 2022 | KeyBanc Capital Markets | Initiation | Overweight | $47 |
| June 23rd 2022 | B. Riley Securities | Initiation | Buy | $53 |
Earnings History & Surprises
PRCTBeat Rate
59%
Last 17 quarters
Avg Surprise
-9.1%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-0.38
Q4 2025
EPS Surprise History
Q1 24
-22.7%
$-0.54vs$-0.44
Q2 24
+7.3%
$-0.51vs$-0.55
Q3 24
+3.8%
$-0.50vs$-0.52
Q4 24
+16.7%
$-0.40vs$-0.48
Q1 25
-2.9%
$-0.35vs$-0.34
Q2 25
+8.2%
$-0.45vs$-0.49
Q3 25
+14.6%
$-0.35vs$-0.41
Q4 25
+7.3%
$-0.38vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.32 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.34 | $-0.35 | -2.9% | ✗ MISS |
Q4 2024 | Oct 28, 2024 | $-0.48 | $-0.40 | +16.7% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.52 | $-0.50 | +3.8% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.55 | $-0.51 | +7.3% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.44 | $-0.54 | -22.7% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.53 | $-0.51 | +3.8% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $-0.57 | $-0.56 | +1.8% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $-0.59 | $-0.63 | -6.8% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.53 | $-0.56 | -5.7% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.47 | $-0.51 | -8.5% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.49 | $-0.43 | +12.2% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.47 | $-0.39 | +17.0% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-0.38 | $-0.42 | -10.5% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.42 | $-1.22 | -190.5% | ✗ MISS |
Q3 2021 | Sep 16, 2021 | — | $-0.36 | — | — |
Latest News
Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $47
➖ NeutralBenzinga•Dec 18, 2025, 03:50 PM
UBS Initiates Coverage On PROCEPT BioRobotics with Buy Rating, Announces Price Target of $62
📈 PositiveBenzinga•Dec 12, 2025, 04:13 PM•Also:
PROCEPT BioRobotics shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and lowered the price target from $55 to $38.
📉 NegativeBenzinga•Dec 8, 2025, 05:00 PM
B of A Securities Downgrades PROCEPT BioRobotics to Neutral, Lowers Price Target to $38
📉 NegativeBenzinga•Dec 8, 2025, 01:16 PM
Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51
➖ NeutralBenzinga•Dec 2, 2025, 05:52 PM
TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $50
➖ NeutralBenzinga•Nov 5, 2025, 06:39 PM
Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Lowers Price Target to $50
➖ NeutralBenzinga•Nov 5, 2025, 03:51 PM
Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51
➖ NeutralBenzinga•Nov 5, 2025, 03:26 PM
PROCEPT BioRobotics Sees FY2026 Sales $410.000M-$430.000M vs $427.376M Est
➖ NeutralBenzinga•Nov 4, 2025, 09:08 PM
PROCEPT BioRobotics Affirms FY2025 Sales Guidance of $325.500M vs $326.566M Est
➖ NeutralBenzinga•Nov 4, 2025, 09:08 PM
PROCEPT BioRobotics Q3 EPS $(0.38) Beats $(0.40) Estimate, Sales $83.327M Beat $80.943M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:05 PM
Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $50
📈 PositiveBenzinga•Oct 15, 2025, 03:35 PM
BTIG Reiterates Neutral on PROCEPT BioRoboticsto Neutral
➖ NeutralBenzinga•Sep 16, 2025, 10:28 AM
Oppenheimer Upgrades PROCEPT BioRobotics to Outperform, Announces $60 Price Target
📈 PositiveBenzinga•Sep 2, 2025, 12:22 PM
Procept BioRobotics down after CEO retirement
📉 NegativeSeeking Alpha•Jul 25, 2025, 03:23 PM
Frequently Asked Questions about PRCT
What is PRCT's current stock price?
PROCEPT BioRobotics Corporation (PRCT) is currently trading at $32.06 per share. The stock has moved -2.05% today.
What is the analyst price target for PRCT?
The average analyst price target for PRCT is $52.29, based on 1 analyst.
What sector is PROCEPT BioRobotics Corporation in?
PROCEPT BioRobotics Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is PRCT's market cap?
PROCEPT BioRobotics Corporation has a market capitalization of $1.79 billion, making it a small-cap company.
Does PRCT pay dividends?
No, PROCEPT BioRobotics Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAORT
Artivion, Inc.
$46.55
Mkt Cap: $2.2B
BGM
BGM Group Ltd.
$4.36
Mkt Cap: $0.9B
CLOV
Clover Health Investments, Corp.
$2.58
Mkt Cap: $1.3B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GRDN
Guardian Pharmacy Services, Inc.
$31.54
Mkt Cap: $2.0B
INSP
Inspire Medical Systems, Inc.
$96.54
Mkt Cap: $2.9B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
QDEL
QuidelOrtho Corporation
$28.95
Mkt Cap: $2.0B
SSII
SS Innovations International, Inc.
$5.72
Mkt Cap: $1.1B
TWST
Twist Bioscience Corporation
$32.51
Mkt Cap: $1.9B
Explore stocks similar to PRCT for comparison